Acute Myeloid Leukemia Clinical Trials

162 studies are recruiting for acute myeloid leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 7

1. Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

   This phase II trial tests how well ruxolitinib with tacrolimus and methotrexate work to prevent the development of graft versus host disease in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelody…

   Stage

   Phase 2

   Ages

   2 to 22

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT06128070 on ClinicalTrials.gov

2. Two Step Haplo With Radiation Conditioning

   This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT05031897 on ClinicalTrials.gov

3. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

   This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or…

   Stage

   Phase 1

   Ages

   0 to 21

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT02508038 on ClinicalTrials.gov

4. Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

   This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for pat…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT04986657 on ClinicalTrials.gov

5. Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

   This study is being performed to develop assays to determine the impact of the therapy patients receive for treatment of AML or MDS and to determine if these tests can identify those patients who are at a greater risk for having their disease relapse.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Rochester Medical Center, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT01311258 on ClinicalTrials.gov

6. BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

   The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is: * BXCL701

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Run by

   Eric Stephen Winer, MD

   See if you can join NCT05703542 on ClinicalTrials.gov

7. Study of REM-422 in Patients With AML or Higher Risk MDS

   The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   9 in total

   Run by

   Remix Therapeutics

   See if you can join NCT06297941 on ClinicalTrials.gov

8. Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

   Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   5 in total

   Run by

   Vincerx Pharma, Inc.

   See if you can join NCT06034275 on ClinicalTrials.gov

9. Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

   This is a phase I/II dose escalation study designed to determine the safety and estimate the efficacy of UD-NK cells combined with FLA chemotherapy in patients age 1-24.99 with relapsed or refractory acute myeloid leukemia. PRIMARY OBJECTIVE: I. To determine the safety and recommended phase II dose…

   Stage

   Phase 1

   Ages

   1 to 24

   Site

   Nationwide Children's Hospital, Columbus, Ohio

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05503134 on ClinicalTrials.gov

10. Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

    This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed). Chemotherapy drugs, such as azacitidine, decitabine, and venetoclax, work in differen…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCSF-Fresno, Clovis, California

    Locations

    4 in total

    Run by

    Brian Jonas

    See if you can join NCT04905810 on ClinicalTrials.gov

11. A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done i…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    Edgewood Oncology Inc.

    See if you can join NCT04243785 on ClinicalTrials.gov

12. Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

    An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Kansas Cancer Center, Fairway, Kansas

    Locations

    5 in total

    Run by

    Celyad Oncology SA

    See if you can join NCT04167696 on ClinicalTrials.gov